High-amylose carboxymethyl starch matrices for oral sustained drug-release: In vitro and in vivo evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 65, Issue 3, 2007, Pages 371-378

  Nabais, T ^a   Brouillet, F ^a,b   Kyriacos, S ^c   Mroueh, M ^c   Amores da Silva, P ^d   Bataille, B ^b   Chebli, C ^a   Cartilier, L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIV MONTPELLIER   (France)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^d UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

Author keywords

Amylose; Drug delivery; Excipient; In vitro; In vivo; Matrix; Polymer; Starch; Sustained release; Tablet

Indexed keywords

AMYLOPECTIN; AMYLOSE; CHLOROACETIC ACID; HYLON VII; PARACETAMOL; POLYMER; SODIUM CHLORIDE; STARCH; UNCLASSIFIED DRUG;

ACIDITY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIODEGRADATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SOLUBILITY; EVALUATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TABLET COMPRESSION; TABLET FORMULATION;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ADULT; ALPHA-AMYLASE; AMYLOSE; ANALGESICS, NON-NARCOTIC; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; FASTING; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; REFERENCE VALUES; SODIUM CHLORIDE; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 33847268238     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.12.001     Document Type: Article

References (23)

1. Bilariedis C.G. The structure and interactions of starch with food constituents. Can. J. Physiol. Pharmacol. 69 (1991) 60-78
2. L. Cartilier, I. Moussa, C. Chebli, S. Buczkowski, Substituted Amylose as a Matrix for Sustained Drug Release, U.S. Patent No. 5,879,707.
3. Chebli C., Moussa I., Buczkowski S., and Cartilier L. Substituted amylose as a matrix for sustained drug release. Pharm. Res. 16 9 (1999) 1436-1440
4. Chebli C., and Cartilier L. Effect of some physical parameters on the sustained-drug release properties of substituted amylose matrices. Int. J. Pharm. 193 02 (2000) 167-173
5. 2-2005 3rd International Symposium on Advanced Biomaterials/Biomechanics, Montreal, Canada, April 3-6, 2005, p. 102.
6. Chebli C., Cartilier L., and Hartman N. Substituted amylose as a matrix for sustained-drug release: a biodegradation study. Int. J. Pharm. 222 2 (2001) 183-189
7. 2-2005 3rd International Symposium on Advanced Biomaterials/Biomechanics, Montreal, Canada, April 3-6, 2005, p. 271.
8. L. Cartilier, M. Ungur, C. Chebli, Tablet Formulation for Sustained Drug-release, Canadian Patent Application No. 2,491,665, December 24, 2004, PCT Application PCT/CA2005/001934, December 20, 2005.
9. S. Qureshi, Tablet testing, in: J. Swarbrick (Ed.), Encyclopedia of Pharmaceutical Technology, 2004 Update Supplement, second ed., Marcel Dekker, New York, USA, 2004, pp. 481-490.
10. Food and Drug Administration, Extended Release Oral Dosage Forms: development, evaluation and application of in vitro-in vivo correlations, Center for Drug Evaluation and Research, Rockville, Maryland, 1997, pp. 1-24.
11. Wagner J.G., and Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 53 11 (1964) 1392-1403
12. Huang Y.B., Tsai Y.H., Yang W.C., Chang J.S., Wu P.C., and Takayama K. Once-daily extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm. 58 3 (2004) 607-614
13. Forrest J.A., Clements J.A., and Prescott L.F. Clinical pharmacokinetics of paracetamol. Clin. Pharmacokinet. 7 2 (1982) 93-107
14. Gramatte T., and Richter K. Paracetamol absorption from different sites in the human small intestine. Br. J. Clin. Pharmacol. 37 6 (1994) 608-611
15. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H.L., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extension. Pharm. Res. 19 7 (2002) 921-925
16. Cao Q.R., Choi Y.W., Cui J.H., and Lee B.J. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. J. Control. Release 108 2-3 (2005) 351-361
17. Mattok G.L., and McGilveray I.J. The effect of food intake and sleep on the absorption of acetaminophen. Rev. Can. Biol. 32 Suppl. (1973) 77-84
18. Kawashima Y., Takeuchi H., Hino T., Niwa T., Lin T.L., Sekigawa F., and Ohya M. Preparation of prolonged-release matrix tablet of acetaminophen with pulverized low-substituted hydroxypropylcellulose via wet granulation. Int. J. Pharm. 99 2-3 (1993) 229-238
19. Hernandez J.I., Ghaly E.S., Malave A., and Marti A. Controlled-release matrix of acetaminophen-ethylcellulose solid dispersion. Drug Dev. Ind. Pharm. 20 7 (1994) 1253-1265
20. Dalton J.T., Straughn A.B., Dickason D.A., and Grandolfi G.P. Predictive ability of level A in vitro-in vivo correlation for ringcap controlled-release acetaminophen tablets. Pharm. Res. 18 12 (2001) 1729-1734
21. Mayersohn M. Principles of drug absorption. In: Banker G., and Rhodes C. (Eds). Modern Pharmaceutics. fourth ed. (2002), Marcel Dekker, New York, USA 23-66
22. Perucca E., and Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br. J. Clin. Pharmacol. 7 2 (1979) 201-206
23. Parojcic J., Duric Z., Jovanovic M., Ibric S., and Jovanovic D. Influence of dissolution media composition on drug release and in-vitro/in-vivo correlation for paracetamol matrix tablets prepared with novel carbomer polymers. J. Pharm. Pharmacol. 56 6 (2004) 735-741